Heart Disease Treatment

Vericiguat (VERQUVO) Tablet

$191.00

VERQUVO Tablet offers a valuable treatment option for patients with heart failure with reduced ejection fraction (HFrEF), helping to improve outcomes and quality of life in this patient population.

Strength	Choose an option2.5mg5mg10mg
	Clear

Quantity

Vericiguat (VERQUVO) Tablet quantity

Add to cart

Sku:

N/A

Tag:

Vericiguat

Description

VERQUVO Tablet contains Vericiguat in strengths of 2.5mg, 5mg, and 10mg, serving as a medication primarily prescribed for the treatment of heart failure with reduced ejection fraction (HFrEF) in adults. It works by stimulating the soluble guanylate cyclase (sGC) enzyme, leading to increased cyclic guanosine monophosphate (cGMP) levels, which in turn promotes vasodilation and reduces cardiac workload.

Key Features:

• Heart Failure Treatment: VERQUVO Tablet is indicated for the management of chronic heart failure with reduced ejection fraction (HFrEF) in adult patients who have recently been hospitalized for worsening heart failure or require intravenous (IV) diuretics.
• Vericiguat Mechanism of Action: Vericiguat, the active ingredient in VERQUVO, acts as a stimulator of soluble guanylate cyclase (sGC), leading to the production of cyclic guanosine monophosphate (cGMP). Increased cGMP levels promote vasodilation and reduce cardiac preload and afterload, thereby improving cardiac function and reducing heart failure symptoms.
• Multiple Strengths: Available in three strengths (2.5mg, 5mg, and 10mg), allowing for individualized dosing based on patient characteristics, including renal function and tolerability.
• Oral Administration: VERQUVO Tablet is administered orally, typically once daily, with or without food, offering convenient dosing for patients with heart failure.
• Clinical Efficacy: Clinical trials have demonstrated the efficacy of Vericiguat in reducing the risk of cardiovascular death or heart failure hospitalization and improving symptoms and functional capacity in patients with HFrEF.
• Combination Therapy: VERQUVO may be used as adjunctive therapy to standard heart failure treatments, including beta-blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs).
• Adverse Effects: Common side effects of VERQUVO may include hypotension (low blood pressure), anemia, dizziness, and renal impairment. Patients should be monitored closely for adverse reactions and managed accordingly.
• Individualized Treatment Approach: The selection of the appropriate VERQUVO dosage and treatment duration should be based on factors such as patient’s clinical status, tolerability, and response to therapy.

Additional information